


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



wherein

n represents an integer of 0 to 6;

R¹ represents hydrogen or C₁₋₆ alkyl;

R² and R³ together with the nitrogen atom to which they are attached, form a 3-8 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,

wherein

said saturated heterocyclic ring ~~is optionally having~~ has one or more substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino,

oxo, aminocarbonyl, C₁₋₆ alkoxy carbonyl, and C₁₋₆ alkyl optionally substituted by hydroxy, carboxy, C₁₋₆ alkoxy, or C₁₋₆ alkoxy carbonyl,

or

R² represents C₂₋₆ alkenyl, C₂₋₆ alkynyl, or C₁₋₆ alkyl substituted by amino, hydroxy, C₁₋₆ alkylamino, or di(C₁₋₆ alkyl)amino;

R³ represents hydrogen, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or C₁₋₆ alkyl optionally substituted by amino, hydroxy, C₁₋₆ alkylamino, or di(C₁₋₆ alkyl)amino; and

R⁴ represents hydrogen halogen, C₁₋₆ alkylthio, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri- halogen, or C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen.

2. (Currently amended) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

n represents an integer of 0 or 1;

R¹ represents hydrogen;

R² and R³ together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen[,] and nitrogen,

wherein

said saturated heterocyclic ring ~~is optionally having~~ has one or more substituents selected from the group consisting of benzyl, hydroxy, carboxy, oxo, aminocarbonyl, C₁₋₆ alkoxy carbonyl, and C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy, or C₁₋₆ alkoxy carbonyl,

or

R² represents C₁₋₆ alkyl substituted by hydroxy, amino, C₁₋₆ alkylamino, or di(C₁₋₆ alkyl)amino;

R³ represents hydrogen, C₁₋₆ alkyl optionally substituted by hydroxy, amino, C₁₋₆ alkylamino, or di(C₁₋₆ alkyl)amino; and

R⁴ represents hydrogen halogen, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen.

3. (Original) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

n represents an integer of 0 or 1;

R¹ represents hydrogen;

R² and R³ together with the nitrogen atom to which they are attached, form a pyrrolidinyl optionally substituted by oxo, piperidino optionally substituted by hydroxy, carboxy, aminocarbonyl, C₁₋₆ alkoxy carbonyl, or C₁₋₆ alkyl optionally substituted

by hydroxy, piperazinyl optionally substituted by benzyl, homopiperidino, or morpholinyl,

or

R² represents C₁₋₆ alkyl substituted by hydroxy, or di(C₁₋₆ alkyl)amino;

R³ represents hydrogen, or C₁₋₆ alkyl; and

R⁴ represents hydrogen, fluoro, chloro, bromo, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri- halogen, or C₁₋₆ alkoxy.

4. (Currently amended) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said tetrahydro-naphthalene derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[3-azepan-1-yl-4-(trifluoromethyl)benzyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(3-bromo-4-piperidin-1-ylbenzyl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
 N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
 N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;
 ethyl 1-[5-[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl]amino)-methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate; and
 N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea.

5. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising a tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 in as an active ingredient , plus at least one pharmaceutically acceptable excipient.
6. (Cancelled)
7. (Currently amended) The ~~medicament~~ pharmaceutical composition as claimed in claim 5, wherein said tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)

12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Currently amended) ~~Process~~ A process for controlling ~~an~~ a urological disorder or disease in ~~humans and animals~~ a human or animal ~~by administration of~~ comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.
20. (Currently amended) ~~Process~~ A process for controlling pain in ~~humans and animals~~ a human or animal ~~by administration of~~ comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.
21. (Currently amended) ~~Process~~ A process for controlling an inflammatory disorder or disease in ~~humans and animals~~ a human or animal ~~by administration of~~ comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.

22. (New) The process of claim 19 wherein said urological disorder is urge urinary incontinence or overactive bladder.
23. (New) The process of claim 20 wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.
24. (New) The process of claim 21 wherein said inflammatory disorder or disease is asthma or COPD.
25. (New) A process for controlling a disorder or disease related to pain comprising administering a VR1-antagonistically effective amount of at least one compound according to claim 1.
26. (New) The process of claim 25 wherein said disorder or disease related to pain is disorder or disease related to pain is neuralgia, a neuropathy, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.